Technical Analysis for ENZ - Enzo Biochem, Inc.
|Grade||Last Price||% Change||Price Change|
ENZ closed up 7.71 percent on Thursday, January 17, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical ENZ trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||New Uptrend||Bullish||0.00%|
|Jan 17||Expansion Breakout||Bullish Swing Setup||0.00%|
|Jan 17||Pocket Pivot||Bullish Swing Setup||0.00%|
|Jan 17||Upper Bollinger Band Walk||Strength||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Above Upper BB||Strength||0.00%|
|Jan 17||Overbought Stochastic||Strength||0.00%|
|Jan 17||Up 3 Days in a Row||Strength||0.00%|
|Jan 17||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 16||Expansion Breakout||Bullish Swing Setup||7.71%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ENZ news...
|52 Week High||8.14|
|52 Week Low||2.32|
|200-Day Moving Average||4.5429|
|50-Day Moving Average||3.0426|
|20-Day Moving Average||2.8985|
|10-Day Moving Average||3.161|
|Average True Range||0.1998|
|Chandelier Exit (Long, 3 ATRs )||3.1906|
|Chandelier Exit (Short, 3 ATRs )||2.9194|
|Upper Bollinger Band||3.5694|
|Lower Bollinger Band||2.2276|
|Percent B (%b)||1.15|
|MACD Signal Line||0.0126|
|Market Cap||175.48 Million|
|Num Shares||46.5 Million|
|Price-to-Earnings (P/E) Ratio||-75.40|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.27|
|Resistance 3 (R3)||4.22||4.00||4.18|
|Resistance 2 (R2)||4.00||3.88||4.03||4.15|
|Resistance 1 (R1)||3.89||3.80||3.95||3.94||4.13|
|Support 1 (S1)||3.56||3.55||3.62||3.61||3.41|
|Support 2 (S2)||3.34||3.47||3.37||3.39|
|Support 3 (S3)||3.23||3.34||3.36|
|Support 4 (S4)||3.28|